Should you bypass anticoagulant “bridging” before and after surgery?

Skipping perioperative use of LMWH in low- and moderate-risk patients on warfarin for atrial fibrillation doesn’t increase their risk of stroke or bleeding.

STOP USING LOW MOLECULAR WEIGHT HEPARIN (LMWH) FOR SURGICAL PROCEDURES TO “BRIDGE” LOW- TO MODERATE-RISK PATIENTS WITH ATRIAL FIBRILLATION (CHADS2, SCORE ≤4) WHO ARE RECEIVING WARFARIN. THE RISKS OUTWEIGHT THE BENEFITS.1

STRENGTH OF RECOMMENDATION
B: Based on a single good-quality randomized control trial.


ILLUSTRATIVE CASE
A 75-year-old man comes to your office for surgical clearance before right knee replacement surgery. He has diabetes and high blood pressure, and is taking warfarin for atrial fibrillation. He is scheduled for surgery in a week. What is the safest way to manage his warfarin in the perioperative period?

On the other hand, warfarin—which remains a common choice for anticoagulation—has a 3- to 7-day onset and elimination.3,4 This long clinical half-life presents a special challenge during the perioperative period. To reduce the risk of operative bleeding, the warfarin must be stopped days prior to the procedure, but physicians often worry that this will increase the risk of arterial or venous thromboembolism, including stroke.

An estimated 250,000 patients need perioperative management of their anticoagulation each year.5 As the US population continues to age and the incidence of conditions requiring anticoagulation (particularly atrial fibrillation) increases, this number is only going to rise.6

Current guidelines on bridging. American College of Chest Physicians (ACCP) guidelines recommend transition to "a short-acting anticoagulant, consisting of subcutaneous low molecular weight heparin (LMWH) or intravenous unfractionated heparin, for a 10- to 12-day period during interruption of vitamin K antagonist (VKA) therapy."5 Furthermore, for an appropriate bridging regimen, the ACCP guidelines recommend stopping VKA therapy 5 days prior to the procedure and utilizing LMWH from within 24 to 48 hours of stopping VKA therapy until up to 24 hours before surgery.5 Postoperatively, VKA or LMWH therapy should be reinitiated within 24 hours and 24 to 72 hours,
respectively, depending on the patient’s risk of bleeding during surgery. These guidelines recommend using CHADS2 scoring (Table 3) to determine arterial thromboembolism (ATE) risk in atrial fibrillation. Patients at low risk for ATE (CHADS2 score 0-2) should not be bridged, and patients at high risk (CHADS2 score of 5-6) should always be bridged. These guidelines are less clear about bridging recommendations for moderate-risk patients (CHADS2 score 3-4).

previous evidence on bridging. A 2012 meta-analysis of 34 studies evaluated the safety and efficacy of perioperative bridging with heparin in patients receiving VKA. Researchers found no difference in ATE events in 8 studies that compared groups that received bridging vs groups that simply stopped anticoagulation (odds ratio [OR]=0.80; 95% confidence interval [CI], 0.42–1.54). The group that received bridging had an increased risk of overall bleeding in 13 studies, and of major bleeding in 5 studies. This meta-analysis was limited by poor study quality and variation in the indication for VKA therapy.

A 2015 subgroup analysis of a larger cohort study of patients receiving anticoagulants for atrial fibrillation found an increased risk of bleeding when their anticoagulation was interrupted for procedures (OR for major bleeding=3.84; 95% CI, 2.07-7.14; P<.0001). Douketis et al conducted a randomized trial to clarify the need for and safety of bridging anticoagulation for ATE in patients with atrial fibrillation who were receiving warfarin.

| TABLE |
| CHADS2: Assessment of arterial thromboembolic risk in atrial fibrillation |
| Risk factor (CHADS2) | Score |
| Congestive heart failure | 1 |
| Hypertension | 1 |
| Age >75 years | 1 |
| Diabetes mellitus | 1 |
| Stroke/TIA | 2 |
| Maximum score | 6 |

TIA, transient ischemic attack.

Guidelines are not clear about whether patients at moderate risk of arterial thromboembolism need bridging.

When it comes to stroke/TIA, there’s no advantage to bridging

This double blind, placebo-controlled trial compared bridging with dalteparin, a form of LMWH, to placebo among 1884 patients with atrial fibrillation on warfarin whose anticoagulation therapy needed to be interrupted for an elective procedure. Patients were included if they were receiving warfarin to prevent stroke, and had been on warfarin for at least 12 weeks, with a goal international normalized ratio (INR) of 2.0 to 3.0. Exclusion criteria included having a mechanical heart valve or having a stroke/transient ischemic attack (TIA; 12 weeks prior) or major bleeding (6 weeks prior). Cardiac, intracranial, and intraspinal surgeries were also excluded from the study.

The patients’ mean CHADS2 score was 2.3; 38.3% of patients had a CHADS2 score ≥3, and 9.4% of patients had a history of stroke. Forty-four percent of patients underwent a gastrointestinal procedure, 17.2% underwent a cardiothoracic procedure, and 9.2% underwent an orthopedic procedure.

Patients stopped taking warfarin 5 days before their procedure, and began subcutaneous dalteparin, 100 IU/kg, or an identical placebo 3 days before the procedure. The dalteparin/placebo was stopped 24 hours before the procedure and restarted after the procedure, until the patient’s INR was in the therapeutic range. Warfarin was resumed on the evening of the procedure or the following day.

The primary efficacy outcome was ATE, including stroke, TIA, or systemic embolism. The primary safety endpoint was major bleeding (defined as bleeding at a critical anatomic site, symptomatic or clinically overt bleeding, or a decrease in hemoglobin >2 g/dL). Secondary efficacy and safety outcomes included minor bleeding, acute myocardial infarction, deep vein thrombosis, pulmonary embolism, and death. Outcomes were assessed within 37 days of the procedure.

The incidence of ATE was 0.4% (4 events)
in the no-bridging group vs 0.3% (3 events) in the bridging group (95% CI, -0.6 to 0.8; P=.01 for non-inferiority; P=.73 for superiority). Major bleeding occurred in 1.3% of the no-bridging group (12 events) and in 3.2% of the bridging group (29 events), indicating that no bridging was superior in terms of the major bleeding outcome (number needed to harm [NNH]=53; relative risk [RR]=0.41; 95% CI, 0.20-0.78; P=.005). The no-bridging group also had significantly fewer minor bleeds in comparison to the bridging group (NNH=11; 12% vs 20.9%; P<.001). There were no differences between groups in other secondary outcomes.

**WHAT’S NEW**

High-quality evidence suggests it’s OK to stop warfarin before surgery

This is the largest good-quality study to evaluate perioperative bridging in patients with atrial fibrillation who were at low or moderate risk for ATE (CHADS2 score 0–4). Previous studies suggested bridging increased bleeding and offered limited benefit for reducing the risk of ATE. However, this is the first study to include a large group of moderate-risk patients (CHADS2 score 3–4). This trial provides high-quality evidence to support the practice of simply stopping warfarin in the perioperative period, rather than bridging with LMWH.

**CAVEATS**

Findings might not apply to patients at highest risk

Most patients in this study had a CHADS2 score ≤3. About 3% had a CHADS2 score ≥5 or higher. It’s not clear whether these findings apply to patients with a CHADS2 score of 5 or 6.

This trial categorized ATE risk using the CHADS2 score, rather than the CHADS2-VASc, which includes additional risk factors and may more accurately predict stroke risk. Both patients who received bridging therapy and those who did not had a lower rate of stroke than predicted by CHADS2. This may reflect a limit of the predictive value of CHADS2, but should not have affected the rate of bleeding or ATE outcomes in this study.

**CHALLENGES TO IMPLEMENTATION**

Physicians may hesitate to disregard current guidelines

Strokes are devastating events for patients, families, and physicians, and they pose a greater risk of morbidity and mortality compared to bleeding. However, this study suggests patients who receive bridging have a higher risk of bleeding than stroke, which is in contrast to some physicians’ experience and current recommendations.

A physician caring for a patient who’s had a stroke may be inclined to recommend bridging despite the lack of efficacy and evidence of bleeding risk. Additionally, until guidelines reflect the most current research, physicians may be reluctant to provide care in contrast to these recommendations.

**ACKNOWLEDGEMENT**

The PURLs Surveillance System was supported in part by Grant Number UL1TR0024999 from the National Center For Research Resources, a Clinical Translational Science Award to the University of Chicago. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center For Research Resources or the National Institutes of Health.

Copyright © 2015. The Family Physicians Inquiries Network. All Rights Reserved.

**References**